Calocurb raises $27m Series A as revenue triples on GLP-1 wave
What's the deal? CalocurbDealroom has a profile for this one. Try Dealroom →, the Auckland maker of an appetite-suppressing supplement, has raised $27 million in a Series A round. The company says it is riding the surge in demand tied to GLP-1 weight-loss drugs such as OzempicDealroom has a profile for this one. Try Dealroom → and WegovyDealroom has a profile for this one. Try Dealroom →.
By the numbers: Calocurb tripled its revenue, according to the company. The raise ranks in the 95th percentile among Series A rounds in New Zealand's food sector over the past 48 months.
What's the endgame? The supplement is designed to suppress appetite, positioning Calocurb alongside — rather than against — the booming market for GLP-1 injectable drugs.
Why now? Demand for weight-loss products has climbed sharply as GLP-1 drugs move into the mainstream. Calocurb is presenting its supplement as a natural alternative for consumers drawn to that category.
The signal: A $27 million Series A is a large round for a New Zealand food company, reflecting how far investor appetite for GLP-1-adjacent products now reaches beyond the pharmaceutical giants driving the boom.
Read more: nzherald.co.nz
Image credit: Calocurb
